This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
by Zacks Equity Research
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Bet on 5 Stocks With Strong Earnings Beat Potential
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
Medtronic (MDT) Tops Q2 Earnings on Strong Segmental Growth
by Zacks Equity Research
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
Pacific Biosciences Offers Insights on Aedes aegypti Genome
by Zacks Equity Research
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $308.23, moving -0.95% from the previous trading session.
Is Illumina (ILMN) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks
by Nalak Das
Investors' optimism has been revived on risky assets like equities with a divided U.S. Congress.
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
by Zacks Equity Research
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $322.73 in the latest trading session, marking a -0.43% move from the prior day.
Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings
by Zacks Equity Research
Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings
Go Beyond Earnings Growth, Bet on Beat With 5 Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $292.25, marking a -0.97% move from the previous day.
The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina
Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.
Top Analyst Reports for Procter & Gamble, Philip Morris & Honeywell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Philip Morris (PM) and Honeywell (HON).
Illumina (ILMN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 21.60% and 3.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AMGN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMGN vs. ILMN: Which Stock Is the Better Value Option?
Pacific Biosciences Introduces Enhancements to Sequel System
by Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.